BACKGROUND: Partially due to the rare occurrence of soft tissue and osteogenic sarcomas in the general population, scant attention has been given to their hereditary etiology. Their overall poor prognosis might be ameliorated through an understanding of their environmental and hereditary causal factors, and/or their interactions, thereby contributing to earlier diagnosis and even the development of molecularly based targeted therapy. METHODS: The authors selected 10 sarcoma-prone families from their extensive hereditary cancer-prone family resource and focused on their challenging diagnostic, surveillance, and management features. The family study protocol included the compilation of a detailed family history of malignant disease of all anatomic sites and the collection of all available primary medical and pathology documents for verification. Genetic counseling was provided before DNA collection and at disclosure of results. RESULTS: These families displayed marked phenotypic and genotypic heterogeneity. In one of these families, 16 relatives had sarcomas, with 2 of the 16 each having 2 metachronous sarcomas; to our knowledge, this represents the greatest number of sarcomas reported in any family described to date. Two familial atypical multiple-mole melanoma syndrome kindreds with the CDKN2A mutation showed the association of sarcoma with malignant melanoma, whereas one family had several pancreatic carcinomas. Other families with sarcoma had hereditary nonpolyposis colorectal carcinoma with MSH2 mutation, hereditary breast carcinoma with BRCA1 mutation, and p53 mutation in a Li-Fraumeni syndrome. CONCLUSIONS: Sarcoma-prone families reported in the current study were selected carefully to depict clinicopathology and compliance features, the understanding of which could elucidate the etiologic role of genetic factors in concert with the phenotypic and genotypic heterogeneity encountered in such families. The lack of a population-based data set for these families posed a limitation. Copyright 2003 American Cancer Society.
BACKGROUND: Partially due to the rare occurrence of soft tissue and osteogenic sarcomas in the general population, scant attention has been given to their hereditary etiology. Their overall poor prognosis might be ameliorated through an understanding of their environmental and hereditary causal factors, and/or their interactions, thereby contributing to earlier diagnosis and even the development of molecularly based targeted therapy. METHODS: The authors selected 10 sarcoma-prone families from their extensive hereditary cancer-prone family resource and focused on their challenging diagnostic, surveillance, and management features. The family study protocol included the compilation of a detailed family history of malignant disease of all anatomic sites and the collection of all available primary medical and pathology documents for verification. Genetic counseling was provided before DNA collection and at disclosure of results. RESULTS: These families displayed marked phenotypic and genotypic heterogeneity. In one of these families, 16 relatives had sarcomas, with 2 of the 16 each having 2 metachronous sarcomas; to our knowledge, this represents the greatest number of sarcomas reported in any family described to date. Two familial atypical multiple-mole melanoma syndrome kindreds with the CDKN2A mutation showed the association of sarcoma with malignant melanoma, whereas one family had several pancreatic carcinomas. Other families with sarcoma had hereditary nonpolyposis colorectal carcinoma with MSH2 mutation, hereditary breast carcinoma with BRCA1 mutation, and p53 mutation in a Li-Fraumeni syndrome. CONCLUSIONS:Sarcoma-prone families reported in the current study were selected carefully to depict clinicopathology and compliance features, the understanding of which could elucidate the etiologic role of genetic factors in concert with the phenotypic and genotypic heterogeneity encountered in such families. The lack of a population-based data set for these families posed a limitation. Copyright 2003 American Cancer Society.
Authors: Maria J Baker; Alisa M Goldstein; Patricia L Gordon; Kimberly S Harbaugh; Heath B Mackley; Michael J Glantz; Joseph J Drabick Journal: J Med Genet Date: 2016-01-21 Impact factor: 6.318
Authors: Els van Riel; Margreet Gem Ausems; Frans Bl Hogervorst; Irma Kluijt; Marielle E van Gijn; Jeanne van Echtelt; Karen Scheidel-Jacobse; Eric Fam Hennekam; Rein P Stulp; Yvonne J Vos; G Johan A Offerhaus; Fred H Menko; Johan Jp Gille Journal: Hered Cancer Clin Pract Date: 2010-08-12 Impact factor: 2.857
Authors: Qianxi Feng; Eric Nickels; Ivo S Muskens; Adam J de Smith; W James Gauderman; Amy C Yee; Charite Ricker; Thomas Mack; Andrew D Leavitt; Lucy A Godley; Joseph L Wiemels Journal: Elife Date: 2021-06-22 Impact factor: 8.140
Authors: Veronica P C C Yu; Marco Novelli; Stewart J Payne; Sam Fisher; Rebecca A Barnetson; Ian M Frayling; Ann Barrett; David Goudie; Audrey Ardern-Jones; Ros Eeles; Susan Shanley Journal: Hered Cancer Clin Pract Date: 2009-06-03 Impact factor: 2.857